We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





FlashDx Launches New Respiratory and MRSA/SA Panels at MEDICA 2025

By LabMedica International staff writers
Posted on 17 Nov 2025

FlashDx is introducing two new molecular diagnostic assays at MEDICA 2025—the Respiratory Panel 2 and the MRSA/SA Panel. More...

The launch of these assays further extends FlashDx’s multiplex molecular testing portfolio, reinforcing the company’s commitment to advancing near-patient molecular diagnostics through innovation and automation. FlashDx will also demonstrate its fully automated multiplex molecular diagnostic system, powered by its proprietary sSPRT (semi-Solid Phase Real-Time PCR) technology.

The company is debuting Respiratory Panel 2, which targets additional respiratory pathogens to complement the existing Respiratory Panel 1.1. By broadening organism coverage, the new panel is intended to increase diagnostic flexibility while maintaining a syndromic testing approach. FlashDx is also launching an MRSA/SA Panel for rapid and precise detection of Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA), addressing routine screening and infection control needs in hospitals and clinics.

FlashDx is demonstrating its sSPRT powered platform at MEDICA 2025. The sSPRT platform enables rapid, accurate, and multiplex pathogen detection within a fully integrated “sample-to-result” workflow, designed to meet the growing needs of infectious disease and reproductive health diagnostics. Built to comply with the EU’s stringent IVD Regulation standards, the system maintains full regulatory integrity without sacrificing speed or flexibility. Its expandable, multi-slot instrumentation provides true random access to a wide range of disease panels and sample types—anytime and anywhere—allowing laboratories to scale testing confidently while meeting global quality and safety requirements

Attendees can meet FlashDx in Hall 3, Booth H26 at MEDICA 2025 to review the new assays and discuss opportunities for collaboration. Founded by U.S. and European industry experts with Silicon Valley know-how, FlashDx offers a turnkey, sample-to-answer platform and a portfolio of syndromic infectious disease cartridges, with plans to expand into oncology and other disease areas.

Related Links:
FlashDx

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.